nsc145366

NSC145366 is an inhibitor of Hsp90 activities which targets the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation. NSC145366 increases Hsp90 oligomerization resulting in allosteric inhibition of NTD ATPase activity (IC50=119μM) but does not compete with NTD or CTD-ATP binding.

DNJNAc, also known as 2-Acetamido-1,2-dideoxynojirimycin, is a highly potent and specific inhibitor of β-hexosaminidase (HEX). HEX enzymes catalyze the hydrolysis of terminal non-reducing N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl-β-D-galactosamine (GalNAc) residues from glycoconjugates such as glycoproteins, gangliosides, and glycosaminoglycans. HEX secreted by chondrocytes into the extracellular space contributes to cartilage matrix degradation, and HEX activity is elevated in the synovial fluid of osteoarthritis patients.